ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection and healing. Key marketed products include ORTHOVISC (osteoarthritis), AMVISC/AMVISC Plus (ophthalmic viscoelastic), and HYVISC (equine osteoarthritis). The company relies heavily on strategic partnerships for distribution, including Johnson & Johnson (DePuy Mitek) for ORTHOVISC in the U.S. and Bausch & Lomb for ophthalmic products.

Key Financial Metrics (Year Ended Dec 31, 2005)

Material Changes vs. Prior Period

• Revenue Composition: Total revenue increased 13% to $29.84 million, driven primarily by a $6.54 million increase in contract revenue. This was largely due to a $2.3 million termination fee and $4.24 million in reimbursed costs from the termination of the OrthoNeutrogena agreement in Q3 2005.
• Product Revenue Decline: Product revenue decreased 8% to $20.53 million. This was caused by a significant drop in ORTHOVISC sales to DePuy Mitek (due to distributor overstocking in 2004) and the loss of the Advanced Medical Optics (AMO) contract, which expired in June 2005 after AMO acquired a competing product line.
• Margin Compression: Product gross margin fell from 55% to 46%. Management attributed this to a mid-year product recall ($370,000 cost), a lower margin product mix, and manufacturing inefficiencies.
• Net Income Volatility: Net income decreased 47% to $5.89 million. The 2004 figure was artificially inflated by a one-time $7.04 million tax benefit from the release of a valuation allowance against deferred tax assets, which did not recur in 2005.
• International Growth: Despite domestic headwinds, international sales of ORTHOVISC increased 56% year-over-year, driven by market penetration in Turkey, Canada, and Europe.

Guidance, Outlook, and Risks

• Outlook: Management expects product gross margins to improve in 2006 due to better product mix and higher manufacturing volumes. However, operating expenses are expected to rise due to the implementation of SFAS 123R (stock-based compensation expensing), estimated to increase 2006 expenses by approximately $1.7 million pre-tax.
• Product Pipeline:
  • REDEFYNE (Cosmetic Tissue Augmentation): PMA application filed with FDA in September 2005. CE marking received in Q1 2006. Seeking a new global distribution partner following the termination of the OrthoNeutrogena deal.
  • INCERT (Anti-adhesive): CE marking received in 2004. Pilot human clinical trial for spinal surgery completed in Europe in December 2005.
• Key Risks:
  • Reimbursement Uncertainty: ORTHOVISC sales in the U.S. are hindered by the lack of a unique reimbursement code (J-code) for physician offices, currently relying on a miscellaneous code.
  • Customer Concentration: Three customers accounted for 78% of product revenue in 2005. The loss of Bausch & Lomb or DePuy Mitek would be material.
  • Regulatory Approval: Future success depends on FDA approval for REDEFYNE and INCERT-S, which is not guaranteed.

Investor Verification Checklist

• Reimbursement Status: Verify the current status of the J-code application for ORTHOVISC with the Centers for Medicare and Medicaid Services (CMS) and its impact on U.S. sales velocity.
• OrthoNeutrogena Termination: Confirm the terms of the new distribution partnership for REDEFYNE, as the company is now self-funding development and lacks a commercial partner.
• DePuy Mitek Inventory: Monitor quarterly reports for signs that DePuy Mitek has cleared its 2004 overstock and resumed regular ordering of ORTHOVISC.
• SFAS 123R Impact: Review Q1 2006 earnings to confirm the actual impact of stock-based compensation expensing on net income.
• Product Recall Aftermath: Assess if the Q2 2005 ophthalmic product recall has fully resolved and if sales to Bausch & Lomb have stabilized.